An Observational Study to Assess the Effectiveness of Intravitreal Aflibercept in Routine Clinical Practice tn Patients With Visual Impairment Due to Diabetic Macular Oedema (DMO)
Phase of Trial: Phase IV
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Sponsors Bayer
- 12 Dec 2017 Planned End Date changed from 30 Sep 2019 to 30 Dec 2019.
- 12 Dec 2017 Planned primary completion date changed from 5 Jun 2019 to 30 Dec 2018.
- 01 Aug 2016 New trial record